One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
Laura P. Cohen, MD, MPP1,2,3; Nicolas Isaza, MD2,4; Inmaculada Hernandez, PharmD, PhD5; Gregory D. Lewis, MD1,2; Jennifer E. Ho, MD2,4; Gregg C. Fonarow, MD6,7; Dhruv S. Kazi, MD, MSc, MS2,4,8; Brandon K. Bellows, PharmD, MS9
doi : 10.1001/jamacardio.2023.0077
Importance Adding a sodium-glucose cotransporter-2 inhibitor (SGLT2-I) to standard-of-care treatment in patients with heart failure with preserved ejection fraction (HFpEF) reduces the risk of a composite outcome of worsening heart failure or cardiovascular mortality, but the cost-effectiveness in US patients with HFpEF is uncertain.
State-Level Cardiovascular Mortality Rates Among Hispanic, Non-Hispanic Black, and Non-Hispanic White Populations, 1990 to 2019
Catherine O. Johnson, PhD, MPH1; Nicole K. DeCleene, BS1; Brigette F. Blacker, MPH1; Matthew W. Cunningham, MS1; Aleksandr Aravkin, PhD1,2; Joseph L. Dieleman, PhD1,2; Emmanuela Gakidou, PhD1,2; Mohsen Naghavi, MD, PhD1,2; Modele O. Ogunniyi, MD, MPH3; Peng Zheng, PhD1,2; Gregory A. Roth, MD, MPH1,2,4
doi : 10.1001/jamacardio.2023.0112
Importance Cardiovascular disease (CVD) is the leading cause of death in the US, with considerable variation by both state and race and ethnicity group. Consistent, comparable measures of mortality by specific CVD cause at the state level and by race and ethnicity have not previously been available and are necessary for supporting policy decisions aimed at reducing health inequities.
Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US
Joshua A. Jacobs, PharmD1; Daniel K. Addo, MS1; Alexander R. Zheutlin, MD, MS2; Catherine G. Derington, PharmD, MS1; Utibe R. Essien, MD, MPH3,4; Ann Marie Navar, MD, PhD5,10; Inmaculada Hernandez, PharmD, PhD6; Donald M. Lloyd-Jones, MD, ScM7; Jordan B. King, PharmD, MS1,8; Shreya Rao, MD, MPH5; Jennifer S. Herrick, MS9; Adam P. Bress, PharmD, MS1; Ambarish Pandey, MD, MSCS5
doi : 10.1001/jamacardio.2023.0228
Importance The burden of atherosclerotic cardiovascular disease (ASCVD) in the US is higher among Black and Hispanic vs White adults. Inclusion of race in guidance for statin indication may lead to decreased disparities in statin use.
Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma
Jenica N. Upshaw, MD, MS1,2; Jason Nelson, MPH2; Angie Mae Rodday, PhD2; Anita J. Kumar, MD2,3; Andreas K. Klein, MD3; Marvin A. Konstam, MD1; John B. Wong, MD2; Iris Z. Jaffe, MD, PhD1,4; Bonnie Ky, MD5; Jonathan W. Friedberg, MD6; Matthew Maurer, PhD7; David M. Kent, MD2; Susan K. Parsons, MD2,3
doi : 10.1001/jamacardio.2023.0303
Importance Anthracycline-containing regimens are highly effective for diffuse large B-cell lymphoma (DLBCL); however, patients with preexisting heart failure (HF) may be less likely to receive anthracyclines and may be at higher risk of lymphoma mortality.
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials
Ajay J. Kirtane, MD, SM1,2; Andrew S. P. Sharp, MD3; Felix Mahfoud, MD, MA4,5; Naomi D. L. Fisher, MD6; Roland E. Schmieder, MD7; Joost Daemen, MD, PhD8; Melvin D. Lobo, PhD9; Philipp Lurz, MD, PhD10; Jan Basile, MD11; Michael J. Bloch, MD12; Michael A. Weber, MD13; Manish Saxena, MBBS, MSc9; Yale Wang, MD14; Kintur Sanghvi, MD15; J. Stephen Jenkins, MD16; Chandan Devireddy, MD17; Florian Rader, MD, MSc18; Philippe Gosse, MD19; Marc Sapoval, MD20,21,22; Neil C. Barman, MD23; Lisa Claude, MS23; Dimitri Augustin, MD23; Lisa Thackeray, MS24; Christopher M. Mullin, MS24; Michel Azizi, MD, PhD20,21,22; for the RADIANCE Investigators and Collaborators
doi : 10.1001/jamacardio.2023.0338
Importance Ultrasound renal denervation (uRDN) was shown to lower blood pressure (BP) in patients with uncontrolled hypertension (HTN). Establishing the magnitude and consistency of the uRDN effect across the HTN spectrum is clinically important.
Standard vs Augmented Ablation of Paroxysmal Atrial Fibrillation for Reduction of Atrial Fibrillation Recurrence
Girish M. Nair, MBBS, MSc1; David H. Birnie, MB, ChB1; Pablo B. Nery, MD1; Calum J. Redpath, MB, ChB, PhD1; Jean-Francois Sarrazin, MD2; Jean-Francois Roux, MD3; Ratika Parkash, MD4; Martin Bernier, MD5; Laurence D. Sterns, MD6; John Sapp, MD4; Paul Novak, MD6; George Veenhuyzen, MD7; Carlos A. Morillo, MD7; Sheldon M. Singh, MD8; Mouhannad M. Sadek, MD1; Mehrdad Golian, MD1; Andres Klein, MD1; Marcio Sturmer, MD9; Vijay S. Chauhan, MD10; Paul Angaran, MD11; Martin S. Green, MD1; Jordan Bernick, MSc1; George A. Wells, PhD1; Vidal Essebag, MD, PhD5,9
doi : 10.1001/jamacardio.2023.0212
Importance Recurrent atrial fibrillation (AF) commonly occurs after catheter ablation and is associated with patient morbidity and health care costs.
Association of the Timing and Extent of Cardiac Implantable Electronic Device Infections With Mortality
Hui-Chen Han, MBBS, PhD1,2; Jia Wang, MSc3; David H. Birnie, MD4; Marco Alings, MD, PhD5; François Philippon, MD6; Ratika Parkash, MD, MSc7; Jaimie Manlucu, MD8; Paul Angaran, MD9; Claus Rinne, MD10; Benoit Coutu, MD11; R. Aaron Low, MD12; Vidal Essebag, MD, PhD13,14; Carlos Morillo, MD15; Jeffrey S. Healey, MD16; Damian Redfearn, MD17; Satish Toal, MD18; Giuliano Becker, MD14; Michel DeGrâce, MD19; Bernard Thibault, MD20; Eugene Crystal, MD21; Stanley Tung, MD22; John LeMaitre, MD23; Omar Sultan, MD24; Matthew Bennett, MD25; Jamil Bashir, MD1; Felix Ayala-Paredes, MD, PhD26; Philippe Gervais, MD6; Leon Rioux, MD27; Martin E. W. Hemels, MD, PhD28,29; Leon H. R. Bouwels, MD30; Derek V. Exner, MD14; Paul Dorian, MD9; Stuart J. Connolly, MD3; Yves Longtin, MD31; Andrew D. Krahn, MD1
doi : 10.1001/jamacardio.2023.0467
Importance Cardiac implantable electronic device (CIED) infection is a potentially devastating complication with an estimated 12-month mortality of 15% to 30%. The association of the extent (localized or systemic) and timing of infection with all-cause mortality has not been established.
Modeling the Association of Volume vs Composite Outcome Thresholds With Outcomes and Access to Transcatheter Aortic Valve Implantation in the US
Adam J. Nelson, MBBS, MBA, MPH, PhD1; Zachary K. Wegermann, MD1; Dianne Gallup, MS1; Sean O’Brien, PhD1; Andrzej S. Kosinski, PhD1; Vinod H. Thourani, MD2; Dharam J. Kumbhani, MD, SM3; Ajay Kirtane, MD, SM4,5,6; Joseph Allen, MSc7; John D. Carroll, MD8; David M. Shahian, MD9; Nimesh D. Desai, MD, PhD10; Ralph G. Brindis, MD, MPH11; Eric D. Peterson, MD, MPH3; David J. Cohen, MD, MSc5,12; Sreekanth Vemulapalli, MD1
doi : 10.1001/jamacardio.2023.0477
Importance Professional societies and the Centers for Medicare & Medicaid Services suggest volume thresholds to ensure quality in transcatheter aortic valve implantation (TAVI).
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes
Thomas A. Zelniker, MD, MSc1; Stephen D. Wiviott, MD2; Ofri Mosenzon, MD, MSc3; Erica L. Goodrich, MS2; Petr Jarolim, MD, PhD4; Avivit Cahn, MD3; Deepak L. Bhatt, MD, MPH5; Lawrence A. Leiter, MD6; Darren K. McGuire, MD, MHSc7; John Wilding, MD8; Oleg Averkov, MD9; Andrzej Budaj, MD10; Alexander Parkhomenko, MD11; Kausik K. Ray, MBChB12; Ingrid Gause-Nilsson, MD, PhD13; Anna Maria Langkilde, MD, PhD13; Martin Fredriksson, PhD13; Itamar Raz, MD3; Marc S. Sabatine, MD, MPH2,14; David A. Morrow, MD, MPH2
doi : 10.1001/jamacardio.2023.0019
Importance Dapagliflozin reduces the risk of hospitalizations for heart failure and the progression of chronic kidney disease in patients with and without type 2 diabetes (T2D), whereas the effects on reducing atherosclerotic events appear less clear.
Discussing Code Status—Balancing Obligations to Respect Patient Autonomy While Avoiding Harm
Sara S. Inglis, MB, BCh, BAO1
Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure and Preserved Ejection Fraction—Living on the Edge
Alexander T. Sandhu, MD, MS1,2; David J. Cohen, MD, MSc3,4
JAMA Cardiology—The Year in Review, 2022
Robert O. Bonow, MD, MS1,2
Assessing Heart Failure vs Lymphoma Treatment Risks and Benefits—It Takes Two to Tango
Ana Barac, MD, PhD1
A 65-Year-Old Woman With Dyspnea and Recurrent Abdominal Distension
Joseph M. Kim, MD1; Bradley A. Maron, MD2
Worsening Dyspnea and New-Onset Atrial Fibrillation in a 79-Year-Old Woman
Christopher C. Cheung, MD, MPH1; Edward P. Gerstenfeld, MD, MS1
Natural History and Intervention Thresholds for Ascending Thoracic Aortic Aneurysm—Not an Easy Nut to Crack
Mohammad A. Zafar, MBBS1; John A. Elefteriades, MD1
Natural History and Intervention Thresholds for Ascending Thoracic Aortic Aneurysm—Not an Easy Nut to Crack—Reply
Matthew D. Solomon, MD, PhD1,2; David H. Liang, MD, PhD3; Alan S. Go, MD2
More Attention Should Be Paid to Less Severe Nonculprit Lesions
Shichu Liang, MD1; Min Ma, MD, PhD1,2; Yong He, MD1
More Attention Should Be Paid to Less Severe Nonculprit Lesions—Reply
Shamir R. Mehta, MD, MSc1; Natalia Pinilla-Echeverri, MD1; John A. Cairns, MD2
Is There a Role for Renal Denervation in the Treatment of Hypertension?
Clyde W. Yancy, MD, MSc1,2; Gregg C. Fonarow, MD3,4; Patrick T. O’Gara, MD2,5
